HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.

AbstractBACKGROUND:
The current study was conducted to determine characteristics distinguishing the 10-year survivor group in patients with systemic immunoglobulin light chain (AL) amyloidosis who underwent autologous stem cell transplantation (SCT).
METHODS:
The study group included all 74 patients with AL amyloidosis who underwent high-dose melphalan treatment supported by autologous SCT since the beginning of the Mayo Clinic's SCT program until prior to August 2001.
RESULTS:
A total of 32 patients (43%) patients survived for > 10 years. Statistically significant baseline differences in the 10-year survivor group included: 1) the number of organs involved; 2) septal thickness; 3) total cholesterol; and 4) urine total protein. The number of organs involved was the only predictor found on multivariable analysis. Depth of the response to therapy, as measured by the lowest posttransplantation serum free light chain level, was found to be the most significant indicator of durability of response.
CONCLUSIONS:
Autologous SCT can offer durable benefit for patients with AL amyloidosis. The number of organs involved offers the greatest pretreatment prognostic value, whereas the lowest posttransplantation serum free light chain level offers the best posttreatment prognostic value.
AuthorsStefan Cordes, Angela Dispenzieri, Martha Q Lacy, Suzanne R Hayman, Francis K Buadi, David Dingli, Shaji K Kumar, William J Hogan, Morie A Gertz
JournalCancer (Cancer) Vol. 118 Issue 24 Pg. 6105-9 (Dec 15 2012) ISSN: 1097-0142 [Electronic] United States
PMID22707405 (Publication Type: Journal Article)
CopyrightCopyright © 2012 American Cancer Society.
Chemical References
  • Immunoglobulin Light Chains
Topics
  • Adult
  • Aged
  • Amyloidosis (immunology, mortality, therapy)
  • Female
  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation (mortality)
  • Humans
  • Immunoglobulin Light Chains
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Survival Rate
  • Time Factors
  • Transplantation, Autologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: